• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Posaconazole is non-inferior to voriconazole for primary treatment of invasive aspergillosis

byNeel MistryandTeddy Guo
June 25, 2021
in Emergency, Infectious Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Posaconazole  was non-inferior to voriconazole with respect to all-cause mortality at day 42 (15% vs. 21%, respectively).

2. Incidence of treatment-related adverse events was lower for posaconazole than voriconazole. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Invasive aspergillosis (IA) is a life-threatening infection that commonly occurs in patients with immunosuppression. Currently, voriconazole serves as the primary treatment for this condition but there remain concerns regarding its acute and long-term toxicities. Posaconazole, a broad-spectrum triazole, may be used for salvage treatment of IA, but investigations of its efficacy and safety from clinical trials is lacking. This multicenter, randomized controlled trial aimed to assess the non-inferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis. Primary endpoint for this study was cumulative all-cause mortality until day 42 in the intention-to-treat (ITT) population, while secondary endpoints included all-cause mortality until day 84 (ITT), all-cause mortality until day 42 and day 84 in the full-analysis-set (FAS) population, and global clinical response. According to the study, all-cause mortality at day 42 was non-inferior between the posaconazole and voriconazole group. In addition, posaconzaole was well-tolerated, and participants reported fewer treatment-related adverse events. This study was limited by a lack of longitudinal follow-up as outcomes were only reported over a three-month period. Nonetheless, it provides valuable insight regarding the use of posaconazole as a first-line treatment for patients with invasive aspergillosis.

Click to read the study in The Lancet

Relevant Reading: Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation

In-depth [randomized controlled trial]: Between Oct 25, 2013, and Sept 10, 2019, 653 patients were assessed for eligibility across 91 study sites in 26 countries. Included were those aged 13 years and older, weighing ≥ 40 kg, and meeting the criteria for proven, probable, and possible fungal disease. Patients with chronic aspergillosis (> 1-month duration), relapsed or recurrent disease, and significant liver dysfunction were excluded. Altogether, 575 patients (288 in the posaconazole group and 287 in the voriconazole group) were included in the analysis. Among enrolled patients, the median age was 57 years (interquartile range [IQR] 41-66) and 60% were male. Risk factors for IA included prolonged neutropenia (64%), treatment with T-cell immunosuppressant drugs (41%) or corticosteroids (32%), and allogenic hematopoietic stem cell transplantation (22%).

RELATED REPORTS

#VisualAbstract: Azathioprine is associated with an increased incidence of cutaneous squamous cell carcinomas among solid organ transplant recipients

#VisualAbstract: Posaconazole is non-inferior to voriconazole for primary treatment of invasive aspergillosis

Voriconazole superior to amphotericin B for invasive aspergillosis [Classics Series]

The primary endpoint concerning all-cause mortality at day 42 (intention-to-treat population) was 15% (44 of 288) in the posaconazole group and 21% (59 of 287) in the voriconazole group (treatment difference -5.3%, 95% confidence interval [CI] -11.6 to 1.0, p<0.0001). At day 84, a similar pattern was observed between both groups (28% for posaconazole vs. 31% for voriconazole, treatment difference -2.5%, 95% CI -9.9 to 4.9). The secondary endpoint of all-cause mortality (full-analysis-set population – ITT patients with proven or probable IA) from baseline to day 42 showed non-inferiority for posaconazole (19%) compared to voriconazole (19%, treatment difference 0.3%, 95% CI -8.2 to 8.8). Moreover, global clinical response in the FAS population was similar for both treatment groups at 6 weeks and 12 weeks from baseline. The incidence of treatment-related adverse event rates in the ITT population was also lower for posaconazole (30%) than voriconazole (40%, treatment difference -10.2%, 95% CI -17.9 to -2.4). Overall, findings from this study support the use of posaconazole as a first-line treatment for invasive aspergillosis given its high tolerability and minimal treatment-related side effects.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antifungal therapyaspergillosisfungalinvasive aspergillosisPosaconazolevoriconazole
Previous Post

Use of opioids in first trimester not associated with greater risk of congenital malformations

Next Post

#VisualAbstract: Positive Anti-Spike or Anti-Nucleocapsid Antibody Status is Associated with Reduced Incidence of SARS-CoV-2 Reinfection in Health Care Workers

RelatedReports

#VisualAbstract: Azathioprine is associated with an increased incidence of cutaneous squamous cell carcinomas among solid organ transplant recipients
StudyGraphics

#VisualAbstract: Azathioprine is associated with an increased incidence of cutaneous squamous cell carcinomas among solid organ transplant recipients

December 12, 2021
#VisualAbstract: Progression of COVID-19 reduced after high-titer convalescent plasma administration
StudyGraphics

#VisualAbstract: Posaconazole is non-inferior to voriconazole for primary treatment of invasive aspergillosis

February 23, 2021
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]
General Medicine Classics

Voriconazole superior to amphotericin B for invasive aspergillosis [Classics Series]

November 18, 2015
New drug for Chagas disease shows antitrypanosomal activity [CHAGASAZOL trial]
Cardiology

2 Minute Medicine Rewind May 12 – May 19, 2014

May 19, 2014
Next Post
#VisualAbstract: Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma

#VisualAbstract: Positive Anti-Spike or Anti-Nucleocapsid Antibody Status is Associated with Reduced Incidence of SARS-CoV-2 Reinfection in Health Care Workers

Poor cardiovascular health associated with subclinical atherosclerosis in apparently healthy sub-Saharan African populations

#VisualAbstract: Addition of palbociclib to adjuvant endocrine therapy does not improve survival in patients with HR⁺, HER2- breast cancer

#VisualAbstract: Addition of palbociclib to adjuvant endocrine therapy does not improve survival in patients with HR⁺, HER2- breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer
  • Several factors influence health programs conducted in the African American Church
  • Imiquimod noninferior to surgery in management of vulvar high-grade squamous intraepithelial lesions
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.